プラズミノゲン活性化剤阻害剤-1/組織プラズミノゲン活性化剤の遺伝子ポリモルフィズムとアロ移植冠動脈疾患の発生
R L Benza1, H E Grenett, R C Bourge
1Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Alabama, USA. rbenza@cardio.dom.uab.edu
Circulation
|November 24, 1998
まとめ
ドナーのPAI-1 2/2遺伝子型は,心臓移植後のアロ移植血管病変 (Tx CAD) のリスクの増加と関連しています. この遺伝子マーカーは,受容者のTxCAD発症を予測するのに役立ちます.
科学分野:
- 心臓病学 心臓病学
- 移植免疫学 移植免疫学
- 遺伝学 遺伝学とは
背景:
- 繊維分解活性障害は,アロ移植血管病変 (Tx CAD) の重症度と関連しています.
- 繊維分解性タンパク質の遺伝子ポリモルフィズムがこの障害に寄与する可能性があります.
研究 の 目的:
- ドナーのフィブリノリートタンパク質の遺伝子型とTx CADの関連性を調査する.
- 特定のゲノタイプがTxCADの発達を予測するかどうかを判断する.
主な方法:
- 48人の心臓アロ移植受容者におけるサザンブロット分析を用いて,ドナープラズミノゲン活性化剤阻害剤-1 (PAI-1) と組織プラズミノゲン活性化剤 (TPA) の遺伝子型を特定した.
- 遺伝子型がTx CADの発達と相関している.
主要な成果:
- ドナーのTPAゲノタイプとTx CAD.との間には関連性が見つかりませんでした.
- ドナーのPAI-1 2/2遺伝子型は,他の遺伝子型 (P=0.03) と比較して,12ヶ月および24ヶ月でCADの有意に低い自由度 (75%および45%) と関連していました.
- 2/2 PAI-1 遺伝子型アロインプラントの受容者は,より長い不血症の時間を持っていた.
結論:
- ドナー 2/2 PAI-1 ゲノタイプは,Tx CADを発症する重要なリスク因子です.
- この遺伝子型は,Tx CADリスクを予測するためのスクリーニングツールとして役立つ可能性があります.
関連する概念動画
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...


